Llwytho...
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Front Oncol |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Frontiers Media S.A.
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4295550/ https://ncbi.nlm.nih.gov/pubmed/25642417 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2014.00385 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|